In:
Acta Haematologica, S. Karger AG, Vol. 118, No. 4 ( 2007), p. 209-214
Abstract:
〈 i 〉 Background/Aims: 〈 /i 〉 The 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 mutation, which has been found in patients with myeloproliferative disorders (MPD), has not yet been evaluated in lymphoproliferative disor- ders by any adequately sensitive techniques. 〈 i 〉 Methods: 〈 /i 〉 We investigated whether low levels of 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 are present in lymphoid neoplasms using a highly sensitive and highly specific amplification refractory mutation system PCR (ARMS-PCR) assay. 〈 i 〉 Results: 〈 /i 〉 While 234 of 237 cases did not carry the 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 allele, it was identified in the bone marrow of 3 B cell lymphoma patients. The mutation was found to be neither associated with the lymphomas per se, nor with any signs, symptoms or laboratory findings of MPD. Moreover, 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 appeared subsequently in the peripheral blood of 2 of the 3 patients. 〈 i 〉 Conclusion: 〈 /i 〉 These findings suggest that 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 arises in the bone marrow of individuals before clinical manifestation of any myeloid disorders. Presence of 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 in bone marrow might therefore increase the risk of future MPD development, just as monoclonal gammopathy of undetermined significance (MGUS) increases the risk of multiple myeloma. We term this phenomenon ‘ 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 of undetermined significance’ (JMUS). Its clinical significance remains to be determined. To our knowledge, these findings represent the first identification of 〈 i 〉 JAK2 〈 /i 〉 〈 sup 〉 V617F 〈 /sup 〉 in the bone marrow of patients without myeloid malignancies.
Type of Medium:
Online Resource
ISSN:
0001-5792
,
1421-9662
Language:
English
Publisher:
S. Karger AG
Publication Date:
2007
detail.hit.zdb_id:
1481888-7
detail.hit.zdb_id:
80008-9
Permalink
